Rafal Kowalczyk is the Head of Financial Planning & Analysis at Senda Biosciences, bringing more than 15 years of experience across financial, commercial, supply chain, and operations management at local and global levels.
Prior to joining Senda, Rafal served in a senior financial planning role at Passage Bio, following nearly four years as finance director at Spark Therapeutics (acquired by Roche), where he held Global P&L and Balance Sheet responsibility for pre- and post-commercialization products across Technical Operations, Technology Development, Corporate Facilities, IT, Commercial Operations and Medical Affairs. Before his career in industry, Rafal spent nearly eight years in finance and financial planning roles at United Technologies (now Raytheon Technologies). Rafal holds an M.B.A. in Finance & Entrepreneurialism from Northeastern University and a B.S. in Finance from Quinnipiac University.